NA Vaccine Institute announced today that Nexavant, an immune enhancer developed by the company, has been selected as a “Next Generation World Class Product” in the “World Class Product” certification program organized by KOTRA, the Korea Trade-Investment Promotion Agency.

Next Generation World Class Goods is a project that supports globalization by selecting items that are likely to enter the top five in global market share within the next seven years.

As a result of the certification, NAVI will receive benefits from more than 10 domestic organizations, including KOTRA, Korea Export-Import Bank, and IBK, such as training and support for overseas market development, preferential financial transactions and consulting, and rewards for meritorious employees, and can use the World Class Product certification logo for marketing.

Immunization enhancers are vaccine additives that increase the immunogenicity of vaccine antigens. It is utilized as a key element for improving existing vaccines or developing premium vaccines, and is also being developed as a treatment for chronic diseases such as cancer.

Nexavant's mass production technology, an immune booster developed by NA Vaccine Institute, has been certified as a national new technology (NET) by the Ministry of Trade, Industry and Energy.

It is an innovative material that can be mass-produced in a stable and uniform manner. It is expected to be a key technology for the development of vaccines and biological drugs.

Immune enhancers, which are difficult to develop due to high technical barriers, are monopolized by a small number of global pharmaceutical companies. “Nexavant is sold through global distributors to create an environment for technology export, while establishing an active open innovation environment, which is expected to increase commercialization and export performance every year,” said an official from NA Vaccine Institute.

“Nexavent has been selected as a next-generation world-class product, which is an opportunity to recognize its technology and productivity,” said Kim Dong-ho, CEO of NA Vaccine Institute. ”We will actively explore overseas markets and develop new drugs to become a truly world-class product.”

Reporter Yeonho Yang yeonho8902@mk.co.kr